Pfizer will cut 300 jobs as it halts development of Alzheimer's and Parkinson's drugs – The Boston Globe

Pfizer will cut 300 jobs as it halts development of Alzheimer’s and Parkinson’s drugs
Globe Staff
The job cuts will occur in Cambridge, Andover, and Groton, Conn., the company said.
By Kenneth Singletary

(FILES) This file photo taken on April 26, 2016 shows the Pfizer company logo in front of Pfizers headquarters in New York. US pharmaceutical giant Pfizer reported on October 31, 2017 that third-quarter profit more than doubled as strength in newer drugs to treat cancer and other illnesses offset the hit from patent expirations. Net income came in at $2.8 billion, compared with just under $1.4 billion in the year-ago period, a quarter that was hit with one-time expenses connected to Pfizer acquisitions. / AFP PHOTO / DON EMMERTDON EMMERT/AFP/Getty Images

Pfizer will cut 300 jobs in Cambridge, Andover, and Groton, Conn., after the company said it would no longer try to develop Alzheimer’s and Parkinson’s drugs, according to the Wall Street Journal.

The company said the cuts would occur over several months.

“This was an exercise to reallocate [spending] across our portfolio, to focus on those areas where our pipeline, and our scientific expertise, is strongest,” Pfizer said in a statement.


An effective drug to treat Alzheimer’s disease has been a kind of Holy Grail in drug development because of heavy demand. Yet successful development of such a drug has been elusive.

Get Today’s Headlines in your inbox:
The day’s top stories delivered every morning.

But other companies, including Cambridge-based Biogen, continue to pursue treatments for Alzheimer’s disease.

Pfizer, one of the world’s largest pharmaceutical companies, is headquartered in New York with its research center in Groton. It also maintains significant research and development operations in Cambridge and La Jolla, Calif.

Let’s block ads! (Why?)

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *